Biotechnology company Odyssey (ODTX.US) has applied for a second US stock market IPO, planning to raise $100 million.

Biotechnology company Odyssey Therapeutics, which is in Phase 2 clinical stage and is dedicated to developing precision therapies for autoimmune diseases, filed an IPO application to the U.S. Securities and Exchange Commission (SEC) last Friday, aiming to raise up to $100 million. Odyssey focuses on developing targeted therapies for autoimmune and inflammatory diseases. The company utilizes its expertise in immunobiology and drug development to identify and inhibit key signaling pathways driving diseases. Its leading projects include oral small molecule candidate drugs targeting RIPK2 and SLC15A4, with the fastest progressing drug showing early clinical efficacy in treating ulcerative colitis, while others are in preclinical development stages. Odyssey aims to address diseases such as inflammatory bowel disease and lupus where treatment options are still limited. The company had previously applied for a $100 million IPO in January 2025, then withdrew in June 2025. Founded in 2021 and headquartered in Boston, Massachusetts, the company reported $3 million in revenue in the 12 months ending on December 31, 2025. Odyssey Therapeutics plans to list on the Nasdaq under the stock symbol ODTX. The company had secretly submitted the application on February 6, 2026. JPMorgan, TD Cowen, Cantor Fitzgerald, Wedbush PacGrow, and Oppenheimer & Co. are the joint bookrunners for the transaction.